A precision medicine approach to stress testing using metabolomics and microribonucleic acids.

IF 1.7 4区 医学 Q3 PHARMACOLOGY & PHARMACY Personalized medicine Pub Date : 2022-04-25 DOI:10.2217/pme-2021-0021
A. Limkakeng, L. Rowlette, A. Hatch, A. Nixon, O. Ilkayeva, D. Corcoran, J. Modliszewski, S. M. Griffin, G. Ginsburg, D. Voora
{"title":"A precision medicine approach to stress testing using metabolomics and microribonucleic acids.","authors":"A. Limkakeng, L. Rowlette, A. Hatch, A. Nixon, O. Ilkayeva, D. Corcoran, J. Modliszewski, S. M. Griffin, G. Ginsburg, D. Voora","doi":"10.2217/pme-2021-0021","DOIUrl":null,"url":null,"abstract":"Both transcriptomics and metabolomics hold promise for identifying acute coronary syndrome (ACS) but they have not been used in combination, nor have dynamic changes in levels been assessed as a diagnostic tool. We assessed integrated analysis of peripheral blood miRNA and metabolite analytes to distinguish patients with myocardial ischemia on cardiac stress testing. We isolated and quantified miRNA and metabolites before and after stress testing from seven patients with myocardial ischemia and 1:1 matched controls. The combined miRNA and metabolomic data were analyzed jointly in a supervised, dimension-reducing discriminant analysis. We implemented a baseline model (T0) and a stress-delta model. This novel integrative analysis of the baseline levels of metabolites and miRNA expression showed modest performance for distinguishing cases from controls. The stress-delta model showed worse performance. This pilot study shows potential for an integrated precision medicine approach to cardiac stress testing.","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":" ","pages":""},"PeriodicalIF":1.7000,"publicationDate":"2022-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Personalized medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2217/pme-2021-0021","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 1

Abstract

Both transcriptomics and metabolomics hold promise for identifying acute coronary syndrome (ACS) but they have not been used in combination, nor have dynamic changes in levels been assessed as a diagnostic tool. We assessed integrated analysis of peripheral blood miRNA and metabolite analytes to distinguish patients with myocardial ischemia on cardiac stress testing. We isolated and quantified miRNA and metabolites before and after stress testing from seven patients with myocardial ischemia and 1:1 matched controls. The combined miRNA and metabolomic data were analyzed jointly in a supervised, dimension-reducing discriminant analysis. We implemented a baseline model (T0) and a stress-delta model. This novel integrative analysis of the baseline levels of metabolites and miRNA expression showed modest performance for distinguishing cases from controls. The stress-delta model showed worse performance. This pilot study shows potential for an integrated precision medicine approach to cardiac stress testing.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
一种使用代谢组学和微小核糖核酸进行压力测试的精确医学方法。
转录组学和代谢组学都有望识别急性冠状动脉综合征(ACS),但它们尚未联合使用,也没有将水平的动态变化作为诊断工具进行评估。我们评估了外周血miRNA和代谢产物分析的综合分析,以在心脏压力测试中区分心肌缺血患者。我们在压力测试前后从7名心肌缺血患者和1:1匹配的对照组中分离并定量了miRNA和代谢产物。在有监督的降维判别分析中,联合分析miRNA和代谢组学数据。我们实现了一个基线模型(T0)和一个应力增量模型。这项新的代谢产物和miRNA表达基线水平的综合分析显示,在区分病例和对照组方面表现平平。应力德尔塔模型表现出较差的性能。这项初步研究显示了一种综合精确医学方法用于心脏压力测试的潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Personalized medicine
Personalized medicine 医学-药学
CiteScore
3.30
自引率
4.30%
发文量
49
审稿时长
6-12 weeks
期刊介绍: Personalized Medicine (ISSN 1741-0541) translates recent genomic, genetic and proteomic advances into the clinical context. The journal provides an integrated forum for all players involved - academic and clinical researchers, pharmaceutical companies, regulatory authorities, healthcare management organizations, patient organizations and others in the healthcare community. Personalized Medicine assists these parties to shape thefuture of medicine by providing a platform for expert commentary and analysis. The journal addresses scientific, commercial and policy issues in the field of precision medicine and includes news and views, current awareness regarding new biomarkers, concise commentary and analysis, reports from the conference circuit and full review articles.
期刊最新文献
Challenges and opportunities in building a health economic framework for personalized medicine in oncology. Developing and validating noninvasive prenatal testing for de novo autosomal dominant monogenic diseases in Vietnam. Budget impact and transferability of cost-effectiveness of DPYD testing in metastatic breast cancer in three health systems. Financial incentives to promote personalized medicine in Europe: an overview and guidance for implementation. Cost-effectiveness of extended DPYD testing before fluoropyrimidine chemotherapy in metastatic breast cancer in the UK.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1